Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland

International Journal of Public Health

Volumn 52, Issue 6, 2007, Pages 372-382

  Galani, Carmen ^a,b   Schneider, Heinz ^a   Rutten, Frans F H ^b  

^a HealthEcon Ltd   (Switzerland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cost effectiveness; Lifestyle; Obesity; Overweight; Prevention; Treatment

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INTERMETHOD COMPARISON; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SURVIVAL; SWITZERLAND; SYSTOLIC BLOOD PRESSURE; WEIGHT CHANGE; WEIGHT REDUCTION;

EID: 38649088269     PISSN: 16618556     EISSN: 1420911X     Source Type: Journal    
DOI: 10.1007/s00038-007-7014-9     Document Type: Article

References (44)

1. Alberti KG, Zimmet PK (1998). Definition, diagnosis and classifi cation of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15(7): 539-53.
2. Anderson KM, Odell PM, Wilson PW, Kannel WB (1991). Cardiovascular disease risk profiles. Am Heart J 12 (A Pt 2): 293-8.
3. Avenell A, Broom J, Brown TJ et al. (2004). Systematic review of the long-term effects and economic consequences of treatments for obe sity and implications for health improvement. Health Technol Assess. 8(21): iii-iv, 1-182 (exchange rate 1 GBP = 2.41277 CHF).
4. Briggs AH (2000). Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17(5): 479-500.
5. Briggs A, Fenn P (1998). Confi dence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 7(8): 723-40.
6. Carels RA, Darby LA, Cacciapaglia HM, Douglass OM (2004). Reducing cardiovascular risk factors in postmenopausal women trough a lifestyle change intervention. Journal of Women's Health 13(4): 412-26.
7. CMA (2005). Comprehensive Meta Analysis Version 2.2.023.September 28, 2005 (www.Meta-Analysis.com).
8. Eddy DM, Schlessinger L, Kahn R (2005). Clinical outcomes and cost-effectiveness of strategies for managing people at risk for diabetes. Ann Intern Med. 143(4): 251-64 (exchange rate 1 USD = 1.20892 CHF).
9. European Agency for the Evaluation of Medicinal Products (1998). Committee for proprietary medicinal products European Public Assessment Report (EPAR): XePical. London; EMEA: p.1-39.
10. Epstein FH, Holland WW. (1983). Prevention of chronic diseases in the community - one disease versus multiple disease strategies. Int J Epidemiol. 12(2): 135-7.
11. Expert Panel (EP). on detection, evaluation, and treatment of high cholesterol in adults. (2001). Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285(19): 2486-97.
12. Fenwick E, O'Brien B, Briggs A (2004). Cost-effectiveness acceptability curve - facts, fallacies and frequently asked questions. Health Econ. 13(5): 405-15.
13. Field AE, Coakley EH, Must A et al. (2001). Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 161(13): 1581-6.
14. Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB (2003). Years of life lost due to obesity. JAMA. 289 (2): 187-193.
15. Gerzeli S, Trricone R, Zolo P, Colangelo I, Busca MR, Gandolfo C (2005). The economic burden of stroke in Italy. The EcLIPSE study: economic longitudinal incidence-based project for stroke evaluation. Neurol Sci 26(2): 72-80.
16. Hakim Z, Wolf A, Garrison LP (2002). Estimating the effect of changes in body mass index on health state preferences. Pharmacoeconomics 20 (6): 393-404.
17. Herman WH, Hoerger TJ, Brandle M et al. (2005). The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142 (5): 323-32 (exchange rate 1 USD = 1.20892 CHF).
18. Jia H, Lubetkin EI (2005). The impact of obesity on health-related quality-of-life in the general adult US population. J Public Health 27(2): 156-64.
19. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (1997). The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 157: 2413-46.
20. Kolominsky-Rabas PL, Heuschmann PU, Marschall D et al. (2006). Lifetyme cost of ischemic stroke in Germany: Results and national projections from a population-based stroke registry. The Erlangen Stroke Project. Stroke, 37: 1179-83.
21. Lindström J, Ilanne-Parikka P, Peltonen M et al. (2006). Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the Finish Diabetes Prevention Study. Lancet 368(9548): 1673-9.
22. Lindström J, Peltonen M, Toumilehtp J (2005). Lifestyle strategies for weight control: Experience from the Finnish Diabetes Prevention Study Proc Nutr Soc 64(1): 81-8.
23. Macran S (2004). The relationship between body mass index and health related quality of life. Discussion paper 190. The University of York, Centre for Health Economics.
24. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR (1898). Menopause and risk factors for coronary heart disease. N Engl J Med 321(10): 641-6.
25. Mähönen M, Rajakangas A-M, Kuulasmaa K, Tunstall-Pedoe H (2000). WHO MONICA coronary event registration data book 1980-1995 Accessed on September 2006 at www.who.com/publications.
26. McGee DL (2005). Body mass index and mortality: A meta-analysis based on person-level data from twenty six observational studies. Ann Epidemiol 15(2): 87-97.
27. Laupacis A, Feeny D, Detsky AS, Tugwell PX (1992). How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146(4): 473-81 (exchange rate 1 USD = 1.20892 CHF).
28. Neilson A, Schneider H (2005). Obesity and its co-morbidities: present and future importance on health status in Switzerland. Soz Praventivmed. 50(2): 78-86.
29. Neumann PJ (2005). Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. Oxford University Press.
30. National Institute for Clinical Excellence (2004). Guidance on the use of orlistat for the treatment of obesity in adults. London. Report no.22 (exchange rate 1 = 2.41277 CHF)
31. National Institute for Clinical Excellence (2004). Guidance on the use of sibutramine for the treatment of obesity in adults. London. Report no.31 (exchange rate 1 £ = 2.41277 CHF).
32. Poirier P, Giles TD, Bray GA et al. (2006). Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect on weight loss. Trtherioscler Thromb Vasc Biol. 26(5): 968-76.
33. Pritchett AM, Foreyt JP, Mann DL (2005). Treatment of the metabolic syndrome: The impact of lifestyle modifi cation. Curr Atheroscler Rep. 7(2): 95-102.
34. Ruof J, Golay A, Berne C, Collin C, Lentz J, Maetzel A (2005). Orlistat in responding obese type 2 diabetic patients: Meta-analysis findings and cost-effectivenesss as rationales for reimbursement in Sweden and Switzerland Int J Obes 29(5): 517-23.
35. Saint S, Vesntra DL, Sullivan SD (1999). The use of meta-analysis in cost-effectiveness analysis Pharmacoeconomics 15(1): 1-8.
36. Schmid A, Schneider H, Golay A, Keller U (2005). Economic burden of obesity and its comorbidities in Switzerland. Soz.-Präventivmed. 50(2): 87-94.
37. Schmitt-Koopmann I, Schwenkglenks M, Spinas GA, Szucs TD (2004). Direct medical costs of type 2 diabetes and its complications in Switzerland. Eur J Public Health. 14(1): 3-9.
38. Sempos CT, Durazo-Arvizu R, McGee DL, Cooper RS, Prewitt TE (1998). The influence of cigarette smoking on the association between body weight and mortality. The Framingham Heart Study revised. Ann Epidemiol. 8(5): 289-300.
39. SNB (2006). Swiss National Bank, Monthly Statistical Bulletin, Accessed September 2006 at www.snb.ch.
40. Sonnenberg FA, Beck JR (1993). Markov models in medical decision making: A practical guide. Med Dec Making 13(4): 322-38.
41. TARMED (2006). Tarif code 00.0510 Accessed September 2006 at Tarif-Browser: www.tarmed.ch/tarif/.
42. Tsai AG, Glick HA, Shera D, Stern L, Samaha FF (2005). Cost-effectiveness of a low-carbohydrate and a standard diet in severe obesity. Obes Res 13(10): 1834-40.
43. World Health Organization (2005). European region, country profi le Switzerland, InfoBase ref: 101551a3, Accessed September 2006 at www.who.com.
44. World Health Organization (2000). Obesity: Preventing and managing the global epidemic. Geneva, WHO Technical Report Series, No. 894. Accessed on September 2006 at http://www.who.int/nutrition/publications/obesity/ en/index.html.